GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab) to include all adult patients with primary ... Read More
Venus Remedies expands global reach with market authorizations in Saudi Arabia and Philippines
Venus Remedies Limited, a prominent player in the global pharmaceutical industry, announced its latest achievement of receiving marketing authorizations for critical healthcare products in Saudi ... Read More
Alembic Pharmaceuticals gets FDA final approval for Paclitaxel Injection USP
Alembic Pharmaceuticals Limited has secured final approval for its abbreviated new drug application (ANDA) for Paclitaxel Injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 ... Read More
Oncternal Therapeutics launches Phase 1b trial of Cirmtuzumab in combination with Paclitaxel in breast cancer
Oncternal Therapeutics, a leading U.S. oncology company, has announced the dosing of the first patient in a phase 1b trial of its investigational drug cirmtuzumab, ... Read More